Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daretabart (hu14.18K322A) plus chemotherapy in relapsed/refractory high-risk neuroblastoma
NCT07549321Phase 3Recruiting
- Sponsor
- Renaissance Pharma
- Start
- Mar 2026
- Primary completion
- Mar 2031
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of daretabart in neuroblastoma, sponsored by Renaissance Pharma. Started Mar 2026; status: recruiting.
02
Drugs
daretabart
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07549321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549321.